The world’s largest generics company has emerged from the past year with a new CEO, a new organizational structure, and a newly improved bottom line.
Sanofi is trying to bounce back from 2013’s patent cliff with the help of one of the industry’s most diverse product portfolios.
Concentration on targeted medicines and diagnostic tests has enabled Roche to expand its strong market position and significantly improve net income.
For many women who want to advance to leadership in the pharmaceutical industry, the HBA provides the essential tools, backed by its members and corporate partners.
Pfizer stuck to its priorities, but the company’s attempt to buy AstraZeneca fell flat.
Novo Nordisk continued to grow into the diabetes market, and is projected to be the No. 1 company in worldwide diabetes sales.